高危多发性骨髓瘤患者 upfront 串联自体非清髓异基因造血干细胞移植：一项长期单中心经验。
Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience.
机构信息
Department of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.
Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
出版信息
Intern Med J. 2022 Jul;52(7):1263-1267. doi: 10.1111/imj.15842. Epub 2022 Jul 9.
The role of upfront non-myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high-risk multiple myeloma (HR-MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR-MM. Two-year progression-free survival was improved in the ASCT-NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival (P = 0.118). These results suggest that ASCT-NMA alloSCT can be considered as upfront therapy in HR-MM.
upfront 非清髓性异基因造血干细胞移植（NMA alloSCT）在高危多发性骨髓瘤（HR-MM）中的作用尚不清楚。我们评估了与单独自体造血干细胞移植（ASCT）相比，ASCT 后接受 NMA alloSCT 治疗新诊断的 HR-MM 的结果。ASCT-NMA alloSCT 组的 2 年无进展生存率提高（44% vs 16%；P=0.035），总生存率也有改善的趋势（P=0.118）。这些结果表明，ASCT-NMA alloSCT 可作为 HR-MM 的一线治疗。
Zotero 插件